Top Page
Pelthos Therapeutics
(PTHS)
Pelthos Therapeutics (PTHS) vs. SPDR S&P 500 ETF (SPY)
Pelthos Therapeutics Business Overview & Revenue Model
Pelthos Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.41M | 0.00 | 0.00 | 0.00 | 0.00 | 199.93K |
| Gross Profit | 4.02M | 0.00 | 0.00 | 0.00 | -209.05K | 61.35K |
| EBITDA | -21.10M | -7.17M | -6.86M | -2.32M | 0.00 | 0.00 |
| Net Income | -23.58M | -7.96M | -7.38M | -2.46M | -595.39K | -660.58K |
Balance Sheet | ||||||
| Total Assets | 126.43M | 1.37M | 96.39K | 55.07K | 0.00 | 71.87K |
| Cash, Cash Equivalents and Short-Term Investments | 14.25M | 513.44K | 96.39K | 55.07K | 0.00 | 0.00 |
| Total Debt | 3.48M | 2.19M | 1.27M | 540.43K | 1.10M | 241.79K |
| Total Liabilities | 68.18M | 4.08M | 6.54M | 3.76M | 3.68M | 3.65M |
| Stockholders Equity | 58.25M | -2.71M | -6.44M | -3.71M | -3.68M | -3.58M |
Cash Flow | ||||||
| Free Cash Flow | -17.01M | -5.79M | -981.03K | -1.57M | -1.59M | -3.63M |
| Operating Cash Flow | -17.01M | -5.79M | -981.03K | -1.57M | -1.59M | -3.63M |
| Investing Cash Flow | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 27.25M | 6.21M | 1.02M | 1.62M | 1.59M | 3.63M |
Pelthos Therapeutics Risk Analysis
Pelthos Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $101.80M | -13.00 | 10.35% | ― | -0.32% | 94.05% | |
56 Neutral | $127.12M | -2.21 | ― | ― | 234.73% | 81.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $77.48M | -1.41 | ― | ― | ― | ― | |
44 Neutral | $78.19M | -0.74 | -398.50% | ― | ― | 30.16% | |
44 Neutral | $48.76M | -0.62 | -50.60% | ― | ― | 1.40% | |
41 Neutral | $63.16M | -1.84 | ― | ― | ― | -234.46% |
Pelthos Therapeutics Corporate Events
On January 12, 2026, Pelthos Therapeutics and its subsidiaries entered into a senior secured venture loan and security agreement with Horizon Technology Finance for a term loan facility of up to $50 million, of which $30 million was funded at closing and an additional $20 million may be drawn upon achieving specified milestones. The facility, maturing in January 2031, carries interest at prime plus 3.75% with interest-only payments through at least early 2029, is secured by substantially all of the borrowers’ assets, and includes customary covenants and default provisions, while Pelthos also issued Horizon five-year warrants to purchase 65,488 common shares at $27.49 per share. According to the company’s January 13, 2026 announcement, the largely non‑dilutive financing is intended to accelerate commercialization of ZELSUVMI, support the launches of Xepi and Xeglyze, and bolster working capital, strengthening Pelthos’ balance sheet and providing growth capital for its expanding dermatology portfolio with limited equity dilution to existing shareholders.
The most recent analyst rating on (PTHS) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
On January 6, 2026, Pelthos Therapeutics’ board, acting on its compensation committee’s annual review, approved revisions to cash and equity compensation for non-employee directors effective January 1, 2026, increasing the annual cash retainer for the Non-Executive Chairman from $50,000 to $60,000 and introducing new cash retainers for members and chairs of the audit, compensation, and nominating and corporate governance committees, while maintaining the base director and committee member retainers. Under the updated policy, non-employee directors may receive an initial equity grant at the board’s discretion when they join, but will not receive recurring annual equity awards, a structure that brings Pelthos’s board pay more in line with its peer group and may support governance stability as the company scales its dermatology portfolio. On January 12, 2026, the company also posted a Q1 2026 corporate presentation outlining its strategy to build a differentiated cutaneous infection franchise around Zelsuvmi and the Xepi and Xeglyze acquisitions, highlighting the large addressable markets, expected product launch timelines through 2027, and a peak net revenue forecast of $175 million per year from Zelsuvmi alone by 2028, signaling an aggressive commercial growth plan aimed at strengthening its position in the dermatology therapeutics market.
The most recent analyst rating on (PTHS) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
On December 23, 2025, Pelthos Therapeutics acquired from Australian biotech Hatchtech all rights and related assets to Xeglyze (abametapir), an FDA-approved topical prescription treatment for head lice, for a total purchase price of $1.8 million, following an earlier $450,000 down payment in November 2025 and completion of the transaction by the scheduled closing date of December 29, 2025. The deal gives Pelthos worldwide commercialization rights to the patent-protected pediculicide without future milestone or royalty obligations, adding a complementary, single-application head-lice therapy with both ovicidal and lousicidal activity to its portfolio and strengthening its commercial infrastructure in dermatology-related conditions, with plans to relaunch the product in 2027 and potentially expand its presence in a sizable pediatric head-lice market.
The most recent analyst rating on (PTHS) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
On December 23, 2025, Pelthos Therapeutics expanded its Board of Directors from seven to eight members and appointed veteran finance executive Andrew J. Einhorn as an independent director, with a term running until the company’s 2026 annual meeting of shareholders. Einhorn, who has more than four decades of experience in investment banking, capital markets and C‑suite finance roles at clinical and commercial-stage life science companies, will serve on Pelthos’ Audit and Compensation Committees and receive standard non-employee director compensation, including a grant of 12,000 restricted stock units vesting on January 1, 2027, and an indemnification agreement consistent with those of other directors and officers. The move brings additional capital markets and strategic financial expertise to Pelthos’ boardroom as the company continues to build out its governance and financial leadership infrastructure following its emergence as a newly public, commercially focused biopharmaceutical company.
The most recent analyst rating on (PTHS) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
On December 17, 2025, Pelthos Therapeutics Inc. conducted its 2025 Annual Meeting of Stockholders where three key proposals were addressed. The election of seven directors to the board was approved, ensuring leadership continuity until the 2026 Annual Meeting. Additionally, stockholders approved a proposal to waive share issuance limits tied to senior secured convertible notes and ratified the appointment of CBIZ CPAs P.C. as the company’s independent auditor for the fiscal year ending December 31, 2025. These decisions reflect robust stakeholder participation and support for the company’s strategic and operational positioning.
The most recent analyst rating on (PTHS) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
Pelthos Therapeutics announced its financial results for the third quarter of fiscal 2025, highlighting the successful commercial launch of ZELSUVMI, an FDA-approved at-home treatment for molluscum contagiosum, which generated $7.1 million in net revenues since its launch in July 2025. The company also completed the acquisition of XEPI, a topical treatment for impetigo, and secured $18 million in financing to support its operations. These developments position Pelthos to capitalize on large market opportunities and unmet needs in pediatric dermatology.
The most recent analyst rating on (PTHS) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
On November 6, 2025, Pelthos Therapeutics acquired the U.S. commercialization rights to Xepi, a topical treatment for impetigo, from Biofrontera and Ferrer. This acquisition adds a complementary product to Pelthos’ portfolio, aimed at addressing antimicrobial resistance in pediatric dermatology. Concurrently, Pelthos closed an $18 million private convertible notes financing with investors, including Ligand Pharmaceuticals, to support the acquisition, relaunch Xepi, and accelerate the commercialization of ZELSUVMI. The financing reflects investor confidence and is expected to strengthen Pelthos’ balance sheet and support its commercial growth.
The most recent analyst rating on (PTHS) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.